维亚生物(01873)于2026年6月22日公告，2026年5月8日至2026年6月5日期间回购的25,317,500股股份已于当日注销，占当时已发行股份总数约1.1887%。按每股回购均价1.387641港元计算，此次回购总金额约为3513.16万港元。注销后，公司已发行股本数目变更为2,104,564,853股，且无库藏股份。
同日，公司在香港联交所场内另行回购510,000股普通股，回购价为每股1.1港元，涉资约56.10万港元；该部分股份尚未注销。购回授权于2025年6月12日获通过，授权购回股份总数为212,843,430股，截至目前，公司已累计购回30,303,000股，占授权通过日已发行股本约1.4237%。
公司确认各项回购行为符合香港联合交易所证券上市规则及相关法律条文的规定。公告由执行董事毛晨签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.